Serum levels of platelet PD-L1 might serve as a more accurate indicator of tumor PD-L1 burden and the likelihood of response to ICI therapy compared to the standard immunohistochemical-based quantification of PD-L1 on biopsy specimens (166). This evidence concerns the gene CD274 and neoplasm.